Members of racial and ethnic minority groups in the US are frequently underrepresented in clinical trials submitted to the US Food and Drug Administration (FDA) to support approval of anticancer therapeutics.1,2 The FDA has long held the view that trials should represent the populations for which the therapeutic is intended to ensure external validity of results. The FDA recommendations to improve trial diversity address the collection and analysis of data on racial and ethnic minority groups, describe considerations for broadening eligibility, and encourage discussions with the appropriate division at the FDA regarding enrollment plans.3,4 External stakeholders have also recommended that pharmaceutical companies develop a plan that outlines measures to ensure diverse clinical trial participation.5 In oncology, a greater reliance on small studies, intermediate and early end points, and innovative trial designs to expedite drug development and approval underscore the need to prospectively define such a plan.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Fashoyin-Aje L, Beaver JA, Pazdur R. Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development. JAMA Oncol. 2021;7(10):1445–1446. doi:10.1001/jamaoncol.2021.2137
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.